Pediatrix Medical Group, Inc.

For the period ended Sep 30, 2025. Filed Nov 3, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 3, 2025

MD$31.29-1.7%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 (Unaudited)

Consolidated Balance Sheets

(in thousands, except share data)

	September 30, 2025	December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents	$340,059	$229,940
Short-term investments	123,042	118,566
Accounts receivable, net	231,122	259,990
Prepaid expenses	8,942	13,410
Income taxes receivable	3,815	12,614
Other current assets	10,215	5,087
Total current assets	717,195	639,607
Property and equipment, net	38,636	39,172
Goodwill	1,255,423	1,242,606
Intangible assets, net	14,802	11,595
Operating and finance lease right-of-use assets	35,702	39,267
Deferred income tax assets	79,758	103,855
Other assets	57,889	76,598
Total assets	$2,199,405	$2,152,700
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$352,233	$398,690
Current portion of debt and finance lease liabilities, net	25,339	20,545
Current portion of operating lease liabilities	12,226	12,704
Income taxes payable	2,749	2,171
Total current liabilities	392,547	434,110
Long-term debt and finance lease liabilities, net	577,169	597,119
Long-term operating lease liabilities	27,533	31,945
Long-term professional liabilities	239,679	257,455
Deferred income tax liabilities	38,285	34,246
Other liabilities	33,526	32,887
Total liabilities	1,308,739	1,387,762
Commitments and contingencies
Shareholders’ equity:
Preferred stock; $.01 par value; 1,000,000 shares authorized; none issued	—	—
Common stock; $.01 par value; 200,000,000 shares authorized; 85,832,837 and 85,866,000 shares issued and outstanding, respectively	858	859
Additional paid-in capital	1,006,197	1,013,690
Accumulated other comprehensive income (loss)	446	(1,071)
Retained deficit	(116,835)	(248,540)
Total shareholders’ equity	890,666	764,938
Total liabilities and shareholders’ equity	$2,199,405	$2,152,700

Consolidated Statements of Income and Comprehensive Income

(in thousands, except per share data)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2025	2024	2025	2024
Net revenue	$492,875	$511,158	$1,420,078	$1,510,555
Operating expenses:
Practice salaries and benefits	332,326	364,888	992,859	1,091,834
Practice supplies and other operating expenses	20,200	29,449	59,500	92,903
General and administrative expenses	60,793	58,121	175,111	174,884
Depreciation and amortization	5,551	6,254	16,196	25,353
Transformational and restructuring related expenses	5,954	18,560	16,393	40,619
Goodwill impairment	—	—	—	154,243
Long-lived asset impairments	—	—	—	27,791
Loss on disposal of businesses	—	59	—	10,932
Total operating expenses	424,824	477,331	1,260,059	1,618,559
Income (loss) from operations	68,051	33,827	160,019	(108,004)
Investment and other income	5,883	1,089	14,347	2,941
Net gain on investments in divested businesses	20,906	—	20,906	—
Interest expense	(8,941)	(10,126)	(27,225)	(31,033)
Equity in earnings of unconsolidated affiliate	1,879	445	2,790	1,427
Total non-operating income (expenses)	19,727	(8,592)	10,818	(26,665)
Income (loss) before income taxes	87,778	25,235	170,837	(134,669)
Income tax (provision) benefit	(16,070)	(5,794)	(39,132)	5,120
Net income (loss)	$71,708	$19,441	$131,705	$(129,549)
Other comprehensive income, net of tax
Unrealized holding gain on investments, net of tax of $101, $571, $496 and $657	309	1,745	1,517	2,005
Total comprehensive income (loss)	$72,017	$21,186	$133,222	$(127,544)
Per common and common equivalent share data:
Net income (loss):
Basic	$0.85	$0.23	$1.56	$(1.56)
Diluted	$0.84	$0.23	$1.54	$(1.56)
Weighted average common shares:
Basic	84,609	83,891	84,649	83,223
Diluted	85,613	84,523	85,559	83,223

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.